Publications since 2019

2021

Marx C, Sonnemann J, Beyer M, Maddocks ODK, Lilla S, Hauzenberger I, Piée‐Staffa A, Siniuk K, Nunna S, Marx‐Blümel L, Westermann M, Wagner T, Meyer FB, Thierbach R, Mullins CS, Kdimati S, Linnebacher M, Neri F, Heinzel T, Wang Z and Krämer OH (2021) Mechanistic insights into p53‐regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells. Mol Oncol, doi: 10.1002/1878-0261.13060 Link

Pons M, Zeyn Y, Zahn S, Mahendrarajah N, Page BDG, Gunning PT, Moriggl R, Brenner W, Butter F and Krämer OH (2021) Oncogenic Kinase Cascades Induce Molecular Mechanisms That Protect Leukemic Cell Models from Lethal Effects of De Novo dNTP Synthesis Inhibition. Cancers (Basel), doi: 10.3390/cancers13143464 Link

Toutah K, Nawar N, Timonen S, Sorger H, Raouf YS, Bukhari S, von Jan J, Ianevski A, Gawel JM, Olaoye OO, Geletu M, Abdeldayem A, Israelian J, Radu TB, Sedighi A, Bhatti MN, Hassan MM, Manaswiyoungkul P, Shouksmith AE, Neubauer HA, de Araujo ED, Aittokallio T, Krämer OH, Moriggl R, Mustjoki S, Herling M and Gunning PT (2021) Development of HDAC Inhibitors Exhibiting Therapeutic Potential in T-Cell Prolymphocytic Leukemia. J Med Chem, doi: 10.1021/acs.jmedchem.1c00420 Link

Göder A, Ginter T, Heinzel T, Stroh S, Fahrer J, Henke A and Krämer OH (2021) STAT1 N-terminal domain discriminatively controls type I and type II IFN signaling. Cytokine, doi: 10.1016/j.cyto.2021.155552 Link

Hassan Z, Schneeweis C, Wirth M, Müller S, Geismann C, Neuß T, Steiger K, Krämer OH, Schmid RM, Rad R, Arlt A, Reichert M, Saur D and Schneider G (2021) Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas. Pancreatology, doi: 10.1016/j.pan.2021.03.012 Link

2020

Schmalohr BF, Mustafa AM, Krämer OH and Imhof D (2020) Structural Insights into the Interaction of Heme with Protein Tyrosine Kinase JAK2*. ChemBioChem, doi: 10.1002/cbic.202000730 Link

Lankes K, Hassan ZZ, Doffo MJ, Schneeweis C, Lier S, Öllinger R, Rad R, Krämer OH, Keller U, Saur D, Reichert M, Schneider G and Wirth M (2020) Targeting the ubiquitin‐proteasome system in a pancreatic cancer subtype with hyperactive MYC. Mol Oncol, doi: 10.1002/1878-0261.12835 Link

Dzulko M, Pons M, Henke A, Schneider G and Krämer OH (2020) The PP2A subunit PR130 is a key regulator of cell development and oncogenic transformation. Biochim Biophys Acta - Rev Cancer, doi: 10.1016/j.bbcan.2020.188453 Link

Sellmer A, Pilsl B, Beyer M, Pongratz H, Wirth L, Elz S, Dove S, Henninger SJ, Spiekermann K, Polzer H, Klaeger S, Kuster B, Böhmer FD, Fiebig H-H, Krämer OH and Mahboobi S (2020) A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia.Eur J Med Chem, doi: 10.1016/j.ejmech.2020.112232 Link

Kiweler N, Wünsch D, Wirth M, Mahendrarajah N, Schneider G, Stauber RH, Brenner W, Butter F and Krämer OH (2020) Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes. J Cancer Res Clin Oncol, doi: 10.1007/s00432-019-03118-4 Link

2019

Beyer M, Romanski A, Mustafa A-HM, Pons M, Büchler I, Vogel A, Pautz A, Sellmer A, Schneider G, Bug G and Krämer OH (2019) HDAC3 Activity is Essential for Human Leukemic Cell Growth and the Expression of ß-catenin, MYC, and WT1.Cancers (Basel), doi: 10.3390/cancers11101436 Link

Heinz KS, Rapp A, Casas-Delucchi CS, Lehmkuhl A, Romero-Fernández I, Sánchez A, Krämer OH, Marchal JA and Cardoso MC (2019) DNA replication dynamics of vole genome and its epigenetic regulation.Epigenetics Chromatin, doi: 10.1186/s13072-019-0262-0 Link

Guo H, Treude F, Krämer OH, Lüscher B and Hartkamp J (2019) PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1. Sci Rep, doi: 10.1038/s41598-019-45209-9 Link